USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Paravax Inc.
Address:
2301 Research Blvd
Fort Collins, CO 80526
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $191,034.00 4
SBIR Phase II $1,230,970.00 2

Award List:

IMPROVEMENTS IN TICK CELL LINE CULTURE

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,632.00
Agency:
HHS
Principal Investigator:
Abstract:
The specific aim of this project is to improve the survival and proliferative ability of tick cell lines. drawing upon recent improvements in the tissue culture of insect cells that have led to the commercial scale-up of recombinant proteins expressed in insect cells, nutritional, physiological,… More

VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,809.00
Agency:
HHS
Principal Investigator:
Xiong, Cheng , Principal Investigator
Abstract:
N/a

CELL CULTURE PRODUCTION OF TOXOPLASMA GONDII TISSUE CYST

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Irene Popiel
Abstract:
N/a

VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Xiong, Cheng , Principal Investigator
Abstract:
P30, the major surface antigen of the toxoplasma gondii tachyzoite stage, has been isolated from the parasite and shown to protect mice from a virulent t. gondii challenge. the cdna encoding p30 had been cloned and expressed in e. coli, producing recombinant protein that was poorly recognized by… More

Lyophilization of a Live Toxoplasma Gondii Vaccine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$41,593.00
Agency:
HHS
Principal Investigator:
Irene Popiel
Abstract:
Toxoplasma gondii strain T-263 is an oocyst negative genetic mutant that induces immunity to oocyst shedding in cats when tissue cysts or bradyzoites are administered orally. The vaccine potential of T-263 has been proven in two separate efficacy studies. The stability of the oocyst-negative… More

CELL CULTURE PRODUCTION OF TOXOPLASMA GONDII TISSUE CYST

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$730,970.00
Agency:
HHS
Principal Investigator:
Irene Popiel
Abstract:
Toxoplasma gondii strain t-263 is an oocyst negativ genetic mutant that induces immunity in cats to wild strains when tissue cysts or bradyzoites are administered orally. the vaccine potential of t-263 has been proven in two separate efficacy studies. use of this feline vaccine will reduce oocyst… More